NBI-31772
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562025

CAS#: 374620-70-9

Description: NBI-31772 is an potent insulin-like growth factor-1 binding protein (IGFBP) inhibitor.


Price and Availability

Size Price Shipping out time Quantity
5mg USD 260 2 Weeks
10mg USD 430 2 Weeks
25mg USD 830 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-03-28. Prices are subject to change without notice.

NBI-31772, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 562025
Name: NBI-31772
CAS#: 374620-70-9
Chemical Formula: C17H11NO7
Exact Mass: 341.0536
Molecular Weight: 341.27
Elemental Analysis: C, 59.83; H, 3.25; N, 4.10; O, 32.82


Synonym: NBI-31772; NBI 31772; NBI31772;

IUPAC/Chemical Name: 1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid

InChi Key: ZCMFEWUYBFMLIN-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H11NO7/c19-11-2-1-7(4-12(11)20)16(23)15-9-6-14(22)13(21)5-8(9)3-10(18-15)17(24)25/h1-6,19-22H,(H,24,25)

SMILES Code: O=C(C1=CC2=C(C(C(C3=CC=C(O)C(O)=C3)=O)=N1)C=C(O)C(O)=C2)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Rinker TE, Philbrick BD, Hettiaratchi MH, Smalley DM, McDevitt TC, Temenoff JS. Microparticle-mediated sequestration of cell-secreted proteins to modulate chondrocytic differentiation. Acta Biomater. 2017 Dec 30. pii: S1742-7061(17)30804-8. doi: 10.1016/j.actbio.2017.12.038. [Epub ahead of print] PubMed PMID: 29292168.

2: Safian D, van der Kant HJG, Crespo D, Bogerd J, Schulz RW. Follicle-Stimulating Hormone Regulates igfbp Gene Expression Directly or via Downstream Effectors to Modulate Igf3 Effects on Zebrafish Spermatogenesis. Front Endocrinol (Lausanne). 2017 Nov 20;8:328. doi: 10.3389/fendo.2017.00328. eCollection 2017. PubMed PMID: 29209278; PubMed Central PMCID: PMC5702253.

3: Lékó AH, Cservenák M, Szabó ÉR, Hanics J, Alpár A, Dobolyi Á. Insulin-like growth factor I and its binding protein-3 are regulators of lactation and maternal responsiveness. Sci Rep. 2017 Jun 13;7(1):3396. doi: 10.1038/s41598-017-03645-5. PubMed PMID: 28611445; PubMed Central PMCID: PMC5469809.

4: Safian D, Morais RD, Bogerd J, Schulz RW. Igf Binding Proteins Protect Undifferentiated Spermatogonia in the Zebrafish Testis Against Excessive Differentiation. Endocrinology. 2016 Nov;157(11):4423-4433. Epub 2016 Sep 30. PubMed PMID: 27689414.

5: Choi WY, Gemberling M, Wang J, Holdway JE, Shen MC, Karlstrom RO, Poss KD. In vivo monitoring of cardiomyocyte proliferation to identify chemical modifiers of heart regeneration. Development. 2013 Feb 1;140(3):660-6. doi: 10.1242/dev.088526. PubMed PMID: 23293297; PubMed Central PMCID: PMC3561784.

6: Hollis ER 2nd, Lu P, Blesch A, Tuszynski MH. IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury. Exp Neurol. 2009 Jan;215(1):53-9. doi: 10.1016/j.expneurol.2008.09.014. Epub 2008 Oct 2. PubMed PMID: 18938163; PubMed Central PMCID: PMC2632606.

7: Schertzer JD, Gehrig SM, Ryall JG, Lynch GS. Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol. 2007 Oct;171(4):1180-8. Epub 2007 Sep 6. PubMed PMID: 17823291; PubMed Central PMCID: PMC1988868.

8: Khawaja XZ. Development of a scintillation proximity assay for human insulin-like growth factor-binding protein 4 compatible with inhibitor high-throughput screening. Anal Biochem. 2007 Jul 1;366(1):80-6. Epub 2007 Mar 18. PubMed PMID: 17482135.

9: Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007 Nov;32(11):2360-8. Epub 2007 Mar 7. PubMed PMID: 17342171.

10: Silha JV, Murphy LJ. The effects of the insulin-like growth factor-I aptamer, NBI-31772, on glucose homeostasis in the mouse. Can J Physiol Pharmacol. 2005 Jul;83(7):557-63. PubMed PMID: 16091781.

11: De Ceuninck F, Caliez A, Dassencourt L, Anract P, Renard P. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res Ther. 2004;6(5):R393-403. Epub 2004 Jun 28. PubMed PMID: 15380039; PubMed Central PMCID: PMC546277.

12: Mackay KB, Loddick SA, Naeve GS, Vana AM, Verge GM, Foster AC. Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo. J Cereb Blood Flow Metab. 2003 Oct;23(10):1160-7. PubMed PMID: 14526226.

13: Liu XJ, Xie Q, Zhu YF, Chen C, Ling N. Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex. J Biol Chem. 2001 Aug 31;276(35):32419-22. Epub 2001 Jul 9. PubMed PMID: 11445558.